A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.

Study Overview

• Status: Completed
• Conditions: End Stage Renal Disease
• Intervention / Treatment: Drug: paricalcitol capsules

• Study Type: Interventional
• Enrollment (Actual): 75
• Phase: Phase 3

Contacts and Locations

Study Locations

• Poland
  • Krakow, Poland
  • Krakow, Poland, 30-501
• United States
  • California
    • Los Angeles, California, United States, 90095
  • Colorado
    • Denver, Colorado, United States, 80230
  • District of Columbia
    • Washington, District of Columbia, United States, 20007
  • Florida
    • Fort Myers, Florida, United States, 33919
    • Tampa, Florida, United States, 33603
  • Georgia
    • Savannah, Georgia, United States, 31405
  • Illinois
    • Evanston, Illinois, United States, 60201
    • Maywood, Illinois, United States, 60153
  • Indiana
    • Indianapolis, Indiana, United States, 46202
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
  • Missouri
    • St. Louis, Missouri, United States, 63110
  • Nevada
    • Las Vegas, Nevada, United States, 89102
  • New York
    • Mineola, New York, United States, 11501
  • Ohio
    • Cincinnati, Ohio, United States, 45220
    • Cincinnati, Ohio, United States, 45206
    • Cleveland, Ohio, United States, 44195
  • Oregon
    • Portland, Oregon, United States, 97210
  • South Carolina
    • Charleston, South Carolina, United States, 29425
  • Tennessee
    • Memphis, Tennessee, United States, 38105
    • Nashville, Tennessee, United States, 37205
  • Texas
    • Houston, Texas, United States, 77030
    • Lubbock, Texas, United States, 79430

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is greater than or equal to 18 years.
• Subject is diagnosed with ESRD and must be on continuous PD 7 days per week for at least 2 months prior to Screening Phase.
• If female, subject is either not of childbearing potential or is of childbearing potential and practicing one of the recommended methods of birth control.
• If female, subject must have a negative serum pregnancy test prior to treatment.
• If female, subject is not breastfeeding.
• Subject is undergoing full PD regimen and is expected to remain on this PD regimen for the duration of the study.
• For those subjects who have been taking a phosphate binder prior to therapy, the subject has been on a stable type of phosphate binder at least 4 weeks prior to the Pre-Treatment Phase.
• For entry into the Pretreatment Phase the subject must have: Calcium level less than or equal to 10.5 mg/dL and Ca x P level less than or equal to 65.
• For entry into the Treatment Phase the subject must have: iPTH greater than or equal to 300 pg/mL, calcium level of 8.0 to 10.5 mg/dL, inclusive, and Ca x P less than or equal to 65.
• Subject has voluntarily signed and dated an IRB approved informed consent.

Exclusion Criteria:

• Subject has history of an allergic reaction or significant sensitivity to drugs similar to the study drug
• Subject has had active peritonitis within 1 month prior to screening phase.
• Subject has had more than one episode of peritonitis within 4 months prior to screening phase.
• Subject has received a partial parathyroidectomy within 1 year prior to screening phase.
• Subject has had acute renal failure within 3 months of screening phase.
• Subject has chronic gastrointestinal disease.
• Subject has taken aluminum-containing phosphate binders for greater than 3 weeks in the last 3 months prior to the screening phase or will require these medications greater than 3 weeks in the study.
• Subject has a current malignancy or clinically significant liver disease.
• Subject has a history of drug or alcohol abuse within 6 months prior to screening phase.
• Subject has evidence of poor compliance with diet, medication, or PD.
• Subject has participated in any investigational drug or device study within 4 weeks prior to the treatment phase.
• Subject is taking maintenance calcitonin, glucocorticoids, or other drugs that may affect calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy.
• For any reason, subject is considered by the investigator to be an unsuitable candidate to receive paricalcitol capsules.
• Subject is known to be HIV positive.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: B	Drug: paricalcitol capsules; baseline iPTH/60; Other Names: Zemplar; ABT-358; paricalcitol
Placebo Comparator: A	Drug: paricalcitol capsules; baseline iPTH/60; Other Names: Zemplar; ABT-358; paricalcitol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels.	12 weeks
The incidence of clinically meaningful hypercalcemia and elevated Ca x P.	12 weeks

Collaborators and Investigators

• Sponsor: Abbott

Study record dates

Study Major Dates

• Study Start: January 1, 2002
• Primary Completion (Actual): November 1, 2002

Study Registration Dates

• First Submitted: March 26, 2008
• First Submitted That Met QC Criteria: March 26, 2008
• First Posted (Estimate): March 28, 2008

Study Record Updates

• Last Update Posted (Estimate): March 28, 2008
• Last Update Submitted That Met QC Criteria: March 26, 2008
• Last Verified: March 1, 2008

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Renal Insufficiency, Chronic; Kidney Diseases; Kidney Failure, Chronic; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Ergocalciferols
• Other Study ID Numbers: 2001-015; R&D/02/655